MA43755A - Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte - Google Patents

Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Info

Publication number
MA43755A
MA43755A MA043755A MA43755A MA43755A MA 43755 A MA43755 A MA 43755A MA 043755 A MA043755 A MA 043755A MA 43755 A MA43755 A MA 43755A MA 43755 A MA43755 A MA 43755A
Authority
MA
Morocco
Prior art keywords
host
graft
prevention
treatment
methods
Prior art date
Application number
MA043755A
Other languages
English (en)
Inventor
John E Ford
Jessica A Sachs
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA43755A publication Critical patent/MA43755A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA043755A 2016-03-14 2017-03-13 Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte MA43755A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US201662420825P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
MA43755A true MA43755A (fr) 2018-11-28

Family

ID=58455657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043755A MA43755A (fr) 2016-03-14 2017-03-13 Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Country Status (12)

Country Link
US (1) US20190077868A1 (fr)
EP (1) EP3430053A1 (fr)
JP (3) JP2019512493A (fr)
KR (2) KR102830639B1 (fr)
CN (2) CN109153721A (fr)
AU (2) AU2017234010B2 (fr)
BR (1) BR112018068625A2 (fr)
CA (1) CA3017758A1 (fr)
IL (1) IL261767A (fr)
MA (1) MA43755A (fr)
MX (2) MX2018011025A (fr)
WO (1) WO2017160700A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3017743A1 (fr) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methode de traitement de la reaction du greffon contre l'hote (gvd)
CA3027286A1 (fr) 2016-06-12 2017-12-21 Millennium Pharmaceuticals, Inc. Methode de traitement de maladie intestinale inflammatoire
WO2018200818A2 (fr) * 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Méthode de traitement de troubles pédiatriques
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
WO1996024673A1 (fr) 1995-02-10 1996-08-15 Leukosite, Inc. Adressines vasculaires de muqueuses et leurs utilisations
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP2399903A1 (fr) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Inhibiteurs de CCR9 et leurs procédés dýutilisation
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2006026759A2 (fr) 2004-09-03 2006-03-09 Genentech, Inc. Antagonistes anti-beta7 humanises et utilisations de ceux-ci
BRPI0616643A2 (pt) * 2005-09-29 2011-06-28 Elan Pharm Inc compostos de carbamato que inibem a adesão leucocitária mediada por vla-4
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
WO2010107752A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
EP3340997B1 (fr) * 2015-08-25 2024-02-14 The UAB Research Foundation Procédés pour la transplantation de cellules souches
CA3017743A1 (fr) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Methode de traitement de la reaction du greffon contre l'hote (gvd)

Also Published As

Publication number Publication date
EP3430053A1 (fr) 2019-01-23
BR112018068625A2 (pt) 2019-07-30
CA3017758A1 (fr) 2017-09-21
IL261767A (en) 2018-10-31
MX2018011025A (es) 2019-01-10
MX2024008740A (es) 2024-07-23
CN117298268A (zh) 2023-12-29
KR20240074903A (ko) 2024-05-28
KR102830639B1 (ko) 2025-07-07
US20190077868A1 (en) 2019-03-14
KR102667332B1 (ko) 2024-05-20
WO2017160700A1 (fr) 2017-09-21
AU2024203289A1 (en) 2024-08-01
KR20180117195A (ko) 2018-10-26
JP2022137024A (ja) 2022-09-21
JP2019512493A (ja) 2019-05-16
JP2025118642A (ja) 2025-08-13
AU2017234010A1 (en) 2018-09-27
AU2017234010B2 (en) 2024-06-13
CN109153721A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
EP3291815A4 (fr) Méthodes de traitement d'une maladie neurodégénérative
EP3534907A4 (fr) Compositions et méthodes de traitement d'une maladie hépatique
EP3490582A4 (fr) Méthodes et compositions de traitement de maladie.
EP3645121A4 (fr) Méthodes de traitement de la maladie de huntington
EP3458589A4 (fr) Compositions et méthodes de traitement de la maladie de huntington
EP3386520A4 (fr) Méthodes de traitement d'une maladie ou d'un trouble oculaire
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA43374A (fr) Méthodes de traitement de tumeurs malignes
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
EP3515505A4 (fr) Traitement vaa de la maladie de huntington
EP3298140A4 (fr) Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
EP3294761A4 (fr) Compositions et méthodes de traitement et de prévention de l'infection pare. coli
EP3402533A4 (fr) Méthodes et compositions pour le traitement d'une maladie neurologique
EP3528852A4 (fr) Méthodes et compositions pour le traitement de la maladie de fabry
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
EP3294345A4 (fr) Formulations de tpp1 et méthodes de traitement de la maladie cln2
EP3285776A4 (fr) Méthodes de traitement d'infections bactériennes
EP3432891A4 (fr) Méthodes de traitement et de prévention d'une infection à c. difficile
EP3846830A4 (fr) Méthodes et compositions pour le traitement de maladie musculo-squelettiques
EP3393468A4 (fr) Méthodes pour le traitement d'une maladie immunodéficiente
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer
EP3592355A4 (fr) Méthodes de traitement et/ou de prévention de la kératose actinique
MA46967A (fr) Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique
EP3007722A4 (fr) Méthodes de traitement de l'hypotension